Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)

Trial Profile

Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Isatuximab (Primary) ; Dexamethasone; Diphenhydramine; Paracetamol; Ranitidine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms ISLAY
  • Sponsors Sanofi
  • Most Recent Events

    • 20 Nov 2017 This trial has been discontinued in Finland.
    • 15 Nov 2017 This trial has been Discontinued in Hungary
    • 21 Mar 2017 Planned End Date changed from 1 Jul 2020 to 25 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top